Glaukos Corp (GKOS) Stock Price & Analysis
Glaukos Corp (GKOS) rose 3.59% to USD 126.34 as of June 10, 2026 at 02:27 UTC, according to Nexqual real-time market data.
GKOS last closed at USD 121.96; the session ranged USD 123.74–129 on volume of 929,244 shares. Market capitalization is $7.42B, with a 52-week range of USD 73.16–148.11 (NYQ). Source: Nexqual, June 10, 2026 at 02:27 UTC.
Key Statistics (as of June 10, 2026 at 02:27 UTC)
| Price | USD 126.34 |
|---|---|
| Change | ▲ 3.59% (up) |
| Previous Close | USD 121.96 |
| Open | USD 123.79 |
| Day Range | USD 123.74 – 129 |
| 52-Week Range | USD 73.16 – 148.11 |
| Volume | 929,244 shares |
| Market Cap | $7.42B |
| Exchange | NYQ |
Technical Analysis (GKOS)
Nexqual's technical model rates GKOS "BUY" based on 4 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 02:27 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 54 (neutral) |
| vs SMA50 | Above (USD 123.89) |
| MACD | -2.17 (negative) |
Analyst Ratings (GKOS)
Wall Street analysts rate GKOS "Strong Buy" based on 12 analysts, with a mean price target of USD 154.5 (range USD 136–170), per Nexqual as of June 10, 2026 at 02:27 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 154.5 |
| High Target | USD 170 |
| Low Target | USD 136 |
| Buy / Hold / Sell | 13 / 0 / 0 |
Earnings (GKOS)
| Next Earnings Date | 2026-07-29 |
|---|---|
| EPS Estimate | USD -0.21 |
| Revenue Estimate | $151.09M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.18 vs est -0.28 ▲ beat |
| 2025-12-31 | USD -0.28 vs est -0.2 ▼ miss |
| 2025-09-30 | USD -0.16 vs est -0.26 ▲ beat |
| 2025-06-30 | USD -0.24 vs est -0.26 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:27 UTC.
Financials & Fundamentals (GKOS)
| Total Revenue | $551.35M |
|---|---|
| Revenue Growth (YoY) | +41.20% |
| Gross Margin | +78.08% |
| Operating Margin | -13.19% |
| Profit Margin | -34.34% |
| ROE | -26.39% |
| Debt / Equity | 15.78 |
| Current Ratio | 5.43 |
| Total Cash | $276.68M |
| Total Debt | $105.87M |
| Free Cash Flow | $6.09M |
Source: Nexqual, June 10, 2026 at 02:27 UTC.
Financial Health Score (GKOS)
Nexqual rates Glaukos Corp's overall financial health "Solid" across five dimensions, as of June 10, 2026 at 02:27 UTC.
| Growth | Strong — Revenue +32% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 78%, operating -13% |
| Balance Sheet | Strong — $277M cash vs $106M debt, net cash position |
| Cash Flow | Mixed — FCF $6M, slim 1.2% margin |
| Efficiency | Critical — ROE -26%, ROA -5.8% |
Ownership (GKOS)
| Insider Ownership | +3.63% |
|---|---|
| Institutional Ownership | +101.98% |
| Shares Outstanding | 58.73M |
| Float | 57.71M |
| Short % of Float | +6.44% |
Source: Nexqual, June 10, 2026 at 02:27 UTC.
Leadership (GKOS)
Glaukos Corp is led by Thomas William Burns (age 64), Chairman & CEO, per Nexqual as of June 10, 2026 at 02:27 UTC.
| Chairman & CEO | Thomas William Burns (age 64) |
|---|---|
| President & COO | Joseph E. Gilliam (age 49) |
| Senior VP & CFO | Alex R. Thurman (age 55) |
| Vice President of Investor Relations & Corporate Affairs | Christopher William Lewis |
| Senior Vice President of Human Resources | Michele M. Allegretto |
Major Backers & Investors (GKOS)
Notable institutional backers of Glaukos Corp include Janus Henderson Group PLC, Primecap Management Company, JANUS INVESTMENT FUND-Janus Henderson Triton Fund, according to Nexqual as of June 10, 2026 at 02:27 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Janus Henderson Group PLC | 9.11% |
| Primecap Management Company | 5.74% |
| JANUS INVESTMENT FUND-Janus Henderson Triton Fund | 2.87% |
| Ameriprise Financial, Inc. | 2.74% |
| Citadel | 2.46% |
| Alliancebernstein L.P. | 2.38% |
| Holocene Advisors, LP | 2.36% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 23.68% |
| Vanguard Group | 19.01% |
| State Street | 3.72% |
Source: Nexqual, June 10, 2026 at 02:27 UTC.
From Glaukos Corp's Latest SEC 10-K Filing (filed 2026-02-23)
Key Strengths & Strategy (as disclosed to the SEC)
- Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally.
- It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor.
- The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
- It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PEN | Penumbra, Inc. | USD 321.06 | ▲ 0.17% |
| ITGR | Integer Holdings Corporation | USD 94.1 | ▲ 2.3% |
| IRTC | iRhythm Holdings, Inc. | USD 113.83 | ▲ 5.3% |
| LIVN | LivaNova PLC | USD 77.17 | ▲ 6.65% |
| CNMD | CONMED Corporation | USD 36.9 | ▲ 4.95% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:27 UTC. This page is informational and not investment advice.